Allen A. Mitchell, M.D. » Slone Epidemiology Center | Boston University
`
`http://www.bu.edu/slone/about/directors/mitchell/
`
`Allen A. Mitchell, M.D.
`
`Director
`Slone Epidemiology Center
`
`Professor of Epidemiology and Pediatrics
`Boston University Schools of Public Health and Medicine
`
`Lecturer on Pediatrics
`Harvard Medical School
`
`allenmit@bu.edu
`
`Education:
`
`B.A., 1967, Washington University
`M.D., 1970, Tufts University School of Medicine
`
`Research Interests:
`
`Allen A. Mitchell is Professor of Epidemiology and Professor of Pediatrics at the Boston University Schools of Public Health and
`Medicine. He obtained his B.A. degree from Washington University in St. Louis in 1966 and his M.D. from Tufts University School
`of Medicine in Boston in 1970. After pediatric residency training at the Boston Floating Hospital for Infants and Children (Tufts-New
`England Medical Center), he joined the Boston Collaborative Drug Surveillance Program where, among other activities, he worked
`with Drs. Slone, Shapiro, and Heinonen in the analysis of Collaborative Perinatal Project data on birth defects and drugs in
`pregnancy. In 1973-75 he was a fellow in pediatric clinical pharmacology at Children’s Hospital in Boston (jointly with the Center for
`the Evaluation of Clinical Procedures at the Harvard School of Public Health), during which time he established the Pediatric Drug
`Surveillance (“PeDS”) Program, an intensive drug surveillance effort focused on the frequency of medication use and adverse
`effects among hospitalized children. In 1975 he joined Drs. Slone and Shapiro at the newly-created Drug Epidemiology Unit (now
`Slone Epidemiology Center) at Boston University, where he continued to direct the PeDS Program. Following his interest in both
`pharmacoepidemiology and birth defects, Dr. Mitchell in 1975 applied the concept of case-control surveillance to the study of
`teratogenesis, and initiated the Slone Birth Defects Study (BDS) which continues to this time, having collected data on prenatal
`exposures from tens of thousands of malformed infants (and controls) identified via birth defects registries in Massachusetts and
`New York State and at participating hospitals in the regions surrounding Philadelphia, Toronto, San Diego, and Nashville. The BDS
`is now one of two data collection components collaborating with the American Academy of Allergy, Asthma, and Immunology in a
`national systematic surveillance effort (Vaccines and Medication in Pregnancy Safety Surveillance—“VAMPSS”) designed to
`evaluate the risks and safety of the wide range of medications taken by pregnant women. Dr. Mitchell also designed and directed a
`practitioner-based “large simple” randomized trial of 84,000 children to assess the safety of pediatric ibuprofen; that practitioner
`(SCOR) network continues to conduct clinically-relevant office-based research. He also designed and directed epidemiologic
`studies to evaluate pregnancy prevention efforts as part of risk management programs associated with isotretinoin (Accutane and
`others) and thalidomide (Thalomid), and designed the Slone Survey. Dr. Mitchell is the author of numerous publications in the fields
`of pediatric and birth defects pharmacoepidemiology and serves on many editorial boards and advisory committees.
`
`Active Studies
`
`Recent Publications
`
`About
`Directors
`Staff
`Dennis Slone
`
`Page 1 of 1
`
`Case IPR2015-01103
`
`CELGENE EXHIBIT 2066